<SEC-DOCUMENT>0001628908-23-000119.txt : 20230802
<SEC-HEADER>0001628908-23-000119.hdr.sgml : 20230802
<ACCEPTANCE-DATETIME>20230802161610
ACCESSION NUMBER:		0001628908-23-000119
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230802
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230802
DATE AS OF CHANGE:		20230802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		231135816

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>evh-20230802.htm
<DESCRIPTION>08.02.2023 8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:7e6d7619-635a-422d-b18f-38f1cc3dbacc,g:e3cef932-9209-412f-83f3-9c1ffa74c22f,d:b144b1c325944c638d23eae522faf752--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20230802</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20230802.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib144b1c325944c638d23eae522faf752_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 2, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)  &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Evolent Health, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:384.75pt"><tr><td style="width:1.0pt"></td><td style="width:109.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:6.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:103.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37415</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">32-0454912</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Commission File Number:&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">22203</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)(zip code)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">571</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:232.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:186.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ib144b1c325944c638d23eae522faf752_7"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August&#160;2, 2023, Evolent Health, Inc. (the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">") issued a press release announcing its financial results for the quarter ended June&#160;30, 2023, a copy of which is furnished herewith as Exhibit 99.1.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="ib144b1c325944c638d23eae522faf752_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Item 8.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Other Events</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Evolent Health, Inc. (the &#8220;Company&#8221;) issued a notice of redemption to the holders of its outstanding 3.50% Convertible Senior Notes due 2024 (the &#8220;Notes&#8221;) on August 2, 2023, pursuant to which it will redeem the outstanding Notes for cash at a price of 100% of the principal amount of the Notes, plus accrued and unpaid interest, if any, on October 13, 2023 (the &#8220;Redemption Date&#8221;). Prior to the Redemption Date, the holders of the Notes are entitled to convert to shares of the Company&#8217;s Class A Common Stock, par value $0.01 per share (the &#8220;Common Stock&#8221;) at a rate of 54.8667 shares per $1,000 principal amount of Notes. In the event any holder delivers a conversion notice as provided in that certain Indenture dated as of August 19, 2020 (the &#8220;Indenture&#8221;) related to the Notes, the Company intends to satisfy its conversion obligation with respect to each $1,000 principal amount of Notes tendered by Physical Settlement (as defined in the Indenture). In the event such conversion would result in a fractional share of Common Stock, an amount in lieu of the fractional share based on the Daily VWAP (as defined in the Indenture) of the Common Stock on the conversion date will be paid in cash by the Company as provided in the Indenture. As of August 2, 2023, $24.3 million aggregate principal amount of the Notes is outstanding. The Company intends to fund the aggregate redemption price using cash on hand.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="ib144b1c325944c638d23eae522faf752_13"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.833%"><tr><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a2q23exhibit991.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a2q23exhibit991.htm">Press Release of Evolent Health, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a2q23exhibit991.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a2q23exhibit991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a2q23exhibit991.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a2q23exhibit991.htm">, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.</span></td></tr></table></div><div id="ib144b1c325944c638d23eae522faf752_16"></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;     </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;             </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:231.00pt"><tr><td style="width:1.0pt"></td><td style="width:82.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:144.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Jonathan D. Weinberg</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jonathan D. Weinberg</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Counsel and Secretary</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:  August&#160;2, 2023 </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2q23exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2f359ea15df242cd9c3ee5401267ddfd_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><img alt="evhnewlogoa.jpg" src="evhnewlogoa.jpg" style="height:133px;margin-bottom:5pt;vertical-align:text-bottom;width:288px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Announces Second Quarter 2023 Results</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WASHINGTON (August&#160;2, 2023) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. (NYSE&#58; EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended June&#160;30, 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights from the second quarter 2023 announcement include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Revenue of $469.1 million, an increase of $149.2 million, or 46.6%, from the three months ended June 30, 2022. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million resulting in a net loss margin of (8.8)%.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Adjusted EBITDA of $47.4 million resulting in an Adjusted EBITDA margin of 10.1%. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Total Lives on Platform of 78.6&#160;million, up from 19.4&#160;million for the three months ended June 30, 2022.</font></div><div style="margin-bottom:3pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Composed of 3.8&#160;million lives in our Performance Suite with an average PMPM of $24.20, 73.0&#160;million in our Specialty Technology and Services Suite with an average PMPM of $0.35 and 1.8&#160;million on our Administrative Services platform with an average PMPM of $14.22.</font></div><div style="margin-bottom:3pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Average unique members of 41.8&#160;million, up from 16.3&#160;million from the three months ended June 30, 2022. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Total cases managed during the quarter for case-based products totaled 15.0&#160;thousand, yielding an average per case revenue of $2,505.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent highlighted the following commercial arrangements to add to the 2023-year sales cycle, taking the total year-to-date count of new operating partnerships to six versus its annual target of six to eight&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Evolent signed a new operating partnership with Molina in the state of Florida, bringing Performance Suite for both cardiology and oncology specialties for Molina&#8217;s Medicaid and health care exchange members across the state&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Evolent also announced a new corporate agreement with a regional, non-profit health plan with over a million members. As part of the agreement Evolent will be replacing several legacy specialty vendors with its Technology and Services solution, helping create a more integrated environment for the health plan.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">In addition to these, Evolent also announced it signed two Technology and Services client expansions with existing operating partners.  Evolent noted that early evidence of marketplace receptivity to the Company&#8217;s integrated approach to specialty care was encouraging given the number of cross sales and strength of the sales pipeline looking forward. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, &#34;We are pleased to report another quarter of strong results. We also had an outstanding quarter of new business momentum, adding two new operating partners plus two expansions and our specialty growth in the quarter, before the impact of acquisitions, was 32%. We are raising our Adjusted EBITDA range for 2023 and have confidence in our medium-term target of $300 million in Adjusted EBITDA run-rate exiting 2024. I want to thank all of Evolent&#8217;s 5,000 employees for their dedication to improving care for our patients living with complex health conditions.&#8221;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Financial Results of Evolent Health, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss non-GAAP financial measures. Definitions of the non-GAAP financial measures, as well as reconciliations of non-GAAP </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial measures to the most directly comparable GAAP financial measures are included in this earnings release. See Financial Statement Presentation and Non-GAAP Financial Measures for more information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Reported Results </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Evolent Health, Inc. reported the following results in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue of $469.1 million and $319.9 million for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of revenue of $351.9 million and $249.7 million for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selling, general and administrative expenses of $90.4 million and $59.0 million for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss attributable to common shareholders of Evolent Health, Inc. of $(41.4) million and $(4.6) million for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Net loss margin of (8.8)% and (1.4)% for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss attributable to common shareholders of Evolent Health, Inc., per basic and diluted share, of $(0.37) and $(0.05) for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total cash and cash equivalents was $142.5 million as of June&#160;30, 2023. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted Results</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted cost of revenue of $351.9 million and $248.5 million for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted selling, general and administrative expenses of $69.6 million and $49.7 million for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted EBITDA of $47.4 million and $21.7 million for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Adjusted EBITDA margin of 10.1% and 6.8% for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted income attributable to common shareholders of $15.8 million and $9.3 million for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Adjusted income per share attributable to common shareholders of $0.14 and $0.10 for the three months ended June&#160;30, 2023 and 2022, respectively.</font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Business Outlook&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe we can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to acquisitions and other events. Such items may, from time to time, include gain on transfer of membership&#59; loss on repayment&#47;extinguishment of debt&#59; gain from equity method investees, change in fair value of contingent consideration, change in tax receivable agreement liability, other income (expense), right-of-use asset impairments, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory expenses, acquisition-related costs, loss from discontinued operations, dividends and accretion on Series A Preferred Stock and certain other items the company believes to be non-indicative of its ongoing operations. Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments are not currently determinable but may be significant.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Third Quarter 2023 Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For the three months ending September 30, 2023, revenue is expected to be in the range of approximately $500 million to $520 million. Adjusted EBITDA is expected to be in the range of approximately $42 million to $47 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Full Year 2023 Guidance </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is reiterating its previously-stated guidance for revenue and raising its Adjusted EBITDA guidance for the year ending December 31, 2023, with revenue expected to be in the range of approximately $1.935 billion to $1.965 billion and Adjusted EBITDA expected to be in the range of approximately $185 million to $200 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This &#34;Business Outlook&#34; section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations are set forth below in &#34;Forward Looking Statements - Cautionary Language&#34; and Evolent Health, Inc.'s filings with the Securities and Exchange Commission (&#34;SEC&#34;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Additional Outlook Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cash deployed for software development is expected to be in the range of $35 million - $40 million for the year ended December 31, 2023.</font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Web and Conference Call Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Evolent Health, Inc. will hold a conference call to discuss its second quarter performance this evening, August&#160;2, 2023, at 5&#58;00 p.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http&#58;&#47;&#47;ir.evolenthealth.com. PLEASE NOTE&#58; Use the following updated numbers to participate by telephone, dial 855.940.9467 or 412.317.6034  for international callers, and reference the &#8220;Evolent call&#8221;. Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the company's website for one week and will be available beginning later this evening. Evolent invites all interested parties to attend the conference call.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Evolent </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent (NYSE&#58; EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Seth Frank</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investor Relations</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sfrank&#64;evolenthealth.com</font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company views the following activities as integral to understanding its non-GAAP financial measures&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">Repositioning costs include severance, termination benefits and related payroll taxes of $4.7 million, dedicated employee costs of $1.7 million and third-party professional services of $4.8 million. Repositioning costs are not part of Evolent&#8217;s normal course of business and are incurred when there is a business reason to enact a repositioning plan. Adjusting for these costs gives a better view of the Evolent&#8217;s normal operating costs. We only adjust costs that (i) are included within selling, general and administrative expenses on the consolidated statement of operations, (ii) meet the criteria outlined within the respective repositioning plan and (iii) does not relate to normal business operations or ongoing activities.</font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.96pt">Dedicated employee costs primarily include project management and technology staff costs needed to migrate acquired businesses to Evolent&#8217;s integrated technology platform and costs related to the consolidation of internal operations, strategies, processes and platforms. Dedicated employee costs are limited to employees that will have no role in ongoing operations and have no planned role at Evolent once the repositioning activities are completed. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.96pt">Professional services costs primarily relate to services provided by a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods. </font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">Acquisition-related costs include but are not limited to integration consultants, investor outreach services, external valuation and accounting advisory services, legal fees and transaction bonuses paid to certain employees. </font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:28pt">Purchase accounting adjustments include amortization expense on intangible assets such as corporate trade names, customer, relationships, provider network contracts and existing technology related to acquisitions and business combinations. We believe it is important for the reader to understand that revenue generated from acquisitions is included within revenue in calculating adjusted income to common shareholders however amortization expense from acquired intangible assets is excluded in determining adjusted income to common shareholders because it does not directly relate to the services performed for the Company&#8217;s customers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to disclosing financial results that are determined in accordance with GAAP, we present Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses, Adjusted Income Attributable to Common Shareholders, Adjusted Income per Common Share Attributable to Common Shareholders, Adjusted EBITDA and Adjusted EBITDA Margin, which are all non-GAAP financial measures, as supplemental measures to help investors evaluate our fundamental operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are defined as cost of revenue and selling, general and administrative expenses, respectively, adjusted to exclude the impact of stock-based compensation expenses, acquisition-related costs and repositioning costs. Management believes Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are useful to investors, because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, benefit from (provision for) income taxes, depreciation and amortization expenses, adjusted to exclude change in the tax receivable agreement liability, gain from equity method investees, changes in fair value of contingent consideration, other income (expense), net, right-of-use asset impairments, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, dividends and accretion on Series A Preferred Stock, acquisition-related costs and loss from discontinued operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes that Adjusted EBITDA is useful to investors because it allows further insight into the period over period operational performance. Management also uses Adjusted EBITDA as a supplemental performance measure because the removal of repositioning costs, acquisition-related costs, severance or non-cash items (e.g. depreciation, amortization, right-of-use asset impairment and stock-based compensation expense) allows us to focus on operational performance. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adjusted EBITDA Margin is as defined Adjusted EBITDA divided by Revenue. Management believes that this measure is useful to investors because it allows further insight into the period over period operational performance. Management also uses Adjusted EBITDA Margin as a supplemental performance measure because it allows the investor to understand operational performance compared to revenues over time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Income Attributable to Common Shareholders is defined as net loss attributable to common shareholders of Evolent Health, Inc. adjusted to exclude gain from equity method investees, other income (expense), net, changes in fair value of contingent consideration, provision (benefit) for income taxes, change in tax receivable agreement liability, purchase accounting adjustments, right-of-use asset impairment, repositioning costs, stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, dividends and accretion on Series A Preferred Stock and acquisition-related costs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Income per Share Attributable to Common Shareholders is defined as Adjusted Income Attributable to Common Shareholders divided by Weighted-Average Common Shares, and reflects the adjustments made in those non-GAAP measures.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes that Adjusted Income Attributable to Common Shareholders and Adjusted Income per Share Attributable to Common Shareholders are useful to investors because excluding non-cash items (e.g. depreciation, </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">amortization and stock-based compensation expenses) allows investors to focus on operational performance. These measures are also useful to management for the same reason.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These adjusted measures do not represent and should not be considered as alternatives to GAAP measurements, and our calculations thereof may not be comparable to similarly entitled measures reported by other companies. A reconciliation of these adjusted measures to their most comparable GAAP financial measures is presented in the tables below. We believe these measures are useful across time in evaluating our fundamental core operating performance.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lives on Platform and Per Member Per Month (&#8220;PMPM&#8221;) Fee</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Evolent Care Partners in risk arrangements and divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, musculoskeletal, advanced imaging and other diagnostics specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for administrative services implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our surgery management and advanced care planning programs in a given period. Members covered for more than one category are counted in each category. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Suite Average PMPM fee is defined as revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to surgery management and advanced care planning programs divided by the number of cases for a given period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where clients cross between multiple products, we only capture members from the product with the maximum number of members.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our change in segments during the first quarter of 2023, the Company changed its presentation of Lives on Platform to reflect the membership that corresponds to quarterly revenue. The Company recast periods prior to the first quarter of 2023 to reflect the current presentation of Lives on Platform, PMPM fees, Cases and Revenue per Case. The current Performance Suite maps to the prior disclosure of the Clinical Solutions Performance Suite. The current Specialty Technology and Services Suite maps to the prior disclosure of the Clinical Solutions New Century Health Technology and Services Suite. The current Administrative Services maps to the prior disclosure of Evolent Health Services segment. There has been no change in the presentation of Cases from prior period.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_4"></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_7"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands, except per share data)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:582.75pt"><tr><td style="width:1.0pt"></td><td style="width:310.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,136&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,939&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,826&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,996&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,938&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,705&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,413&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,444&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,955&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,115&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,887&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,134&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,112&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,409&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,218&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets impairment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,065&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,065&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,822)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,878&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,704&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,572&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928,749&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,427&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,568)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,633)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,923)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,431)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,458)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,353)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,389)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,184)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,293)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,309)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,464)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,457)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(970)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,159)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,323)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,125)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,305)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,475)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before preferred dividends and accretion of Series A Preferred Stock</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,323)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,305)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,938)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,088)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,364)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,411)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,669)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,938)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,278&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,540&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,792&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,411)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,669)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,938)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(420)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,403)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,876)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,605)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,358)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:294.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:96.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,530&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,200&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,069&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,958&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,699&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,054&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,923&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,784&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,556&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,774&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646,831&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,953&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,174&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,676&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,198&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of discount</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633,013&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,986&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380,783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,876&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,829&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093,219&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859,417&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, mezzanine equity and shareholders' equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646,831&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:388.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash and restricted cash used in continuing operations</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,320)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,778)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,347)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,686)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,559)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,509)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,158&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,599&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,433&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_380"></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_410"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted Results of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:75.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Cost of Revenue to <br>Adjusted Cost of Revenue</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,938&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,705&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost of revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,896&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,519&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Selling, General and Administrative Expenses to <br>Adjusted Selling, General and Administrative Expenses</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,389&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,955&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,924&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,294&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling, general and administrative expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,643&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,682&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_22"></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted EBITDA to Net Income (Loss)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Attributable to Common Shareholders of Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:282.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,411)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(67,669)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(9,938)</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net loss margin</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(8.8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1.4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(7.5)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1.6)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,458)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,353)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,389)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,159&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,018)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,134)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,112)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,409)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,218)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,184)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,822&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,878)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets impairment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,065)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,065)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,261)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,261)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,966)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,012)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,676)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,358)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,088)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,364)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,421)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,720)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,878)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,410&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,739&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,909&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,994&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA margin</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_417"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Net Loss Attributable to Common Shareholders to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adjusted Income Attributable to Common Shareholders</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,411)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,588)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,669)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,938)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,548&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,822&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,878)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,018)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,184)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,359)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,562)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,110)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,131)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets impairment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,065)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,065)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,261)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,261)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,966)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,012)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,676)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,358)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,088)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,364)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,421)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,720)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,878)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted income attributable to common shareholders</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,781&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,921&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,858&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted income per share attributable to common shareholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,278&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,071&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,540&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,792&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For periods of net loss, shares used in both the basic and diluted earnings per share calculation represent basic shares as using diluted shares would be anti-dilutive.</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i2f359ea15df242cd9c3ee5401267ddfd_28"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like&#58; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions&#47;expansions, the adoption and launch of a unified brand, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to efficiently integrate NIA into our operations&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial information of NIA and the pro forma financial information of NIA may not be indicative of future results or our financial condition&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to terminate certain leases and recognize impairment charges in connection with our repositioning plan&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution of the healthcare regulatory and political framework&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services and our ability to keep pace with industry standards, technology and our partners&#8217; needs&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, including our acquisitions of IPG and NIA, which could divert management resources, result in unanticipated costs or dilute our stockholders&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport to Molina Healthcare, Inc. may not be realized&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general economic conditions nationally and regionally in our markets, including increasing inflationary pressures and economic and business conditions and the impact thereof on the economy resulting from public health emergencies, epidemics, pandemics or contagious diseases such as the COVID-19 pandemic&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to the failure of any bank in which we deposit our funds, which could reduce the amount of cash we have available to meet our cash commitments and make additional investments&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships and develop our partner relationships over time&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new opportunities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners could limit or negatively impact our profitability&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets for our services&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to audits by CMS and other governmental payers and actions, including whistleblower claims under the False Claims Act&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts in some of our partner and founder contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to managing our offshore operations and cost reduction goals&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing on favorable terms or at all&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation proceedings, government inquiries, reviews, audits or investigations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the manner in which we access personal data and penalties as a result of privacy and data protection laws&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liabilities and reputational risks related to our ability to safeguard the security and privacy of confidential data&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to legal proceedings related to any alleged infringement, misappropriation or violation of third-party intellectual property rights&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on our ability to use, disclose, de-identify or license data and to integrate third-party technologies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make material payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors may contain different terms than comparable agreement we may enter into with unaffiliated third parties&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2025 convertible notes, which, if triggered, could require us to settle the 2025 convertible notes in cash&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interest rate risk under the Credit Agreement and the terms of our Series A Preferred Stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our debt following the NIA acquisition and our ability to meet our obligations&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to service our debt and pay dividends on our Series A Preferred Stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale, including those issuable upon conversion of our Series A Preferred Stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our Series A Preferred Stock has rights, preferences and privileges that are not held by and are preferential to the rights of holders of our Class A common stock, and could in the future substantially dilute the ownership interest of holders of our Class A common stock&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our certificate of incorporation and by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Our periodic reports and other documents filed with the SEC include additional factors that could affect our businesses and </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial performance. Moreover, we operate in a rapidly changing and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances that occur after the date of this release except to the extent expressly required by law.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>evh-20230802.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7e6d7619-635a-422d-b18f-38f1cc3dbacc,g:e3cef932-9209-412f-83f3-9c1ffa74c22f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20230802" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20230802">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230802_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230802_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20230802_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageCoverPage" roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage">
        <link:definition>0000001 - Document - Cover Page Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>evh-20230802_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7e6d7619-635a-422d-b18f-38f1cc3dbacc,g:e3cef932-9209-412f-83f3-9c1ffa74c22f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="evh-20230802.xsd#CoverPageCoverPage"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="extended" id="ida94d640ebcf4453b3be93b2f07755a2_CoverPageCoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7311851a-a26e-436c-bf28-cd4e10979607" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_Security12bTitle_7311851a-a26e-436c-bf28-cd4e10979607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_08d1e2ce-0357-42bd-aea9-db607b6287cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityIncorporationStateCountryCode_08d1e2ce-0357-42bd-aea9-db607b6287cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0ef78876-dff3-43b7-bf7c-3ff45fcced3f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_DocumentType_0ef78876-dff3-43b7-bf7c-3ff45fcced3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3a99cec7-b5d2-4fb0-9361-f6829b06b6d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityRegistrantName_3a99cec7-b5d2-4fb0-9361-f6829b06b6d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f50c9475-5561-4061-af59-34704830b2a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_CityAreaCode_f50c9475-5561-4061-af59-34704830b2a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4f5d47f0-c06e-4a90-89a9-36d1e66541a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_LocalPhoneNumber_4f5d47f0-c06e-4a90-89a9-36d1e66541a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c4d2c76c-1b4b-4914-b1b8-9b4ffea51005" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityFileNumber_c4d2c76c-1b4b-4914-b1b8-9b4ffea51005" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fd79f116-d53e-4c56-9738-19271bdf8e98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityTaxIdentificationNumber_fd79f116-d53e-4c56-9738-19271bdf8e98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_49f8900f-0930-46f9-aee6-831123a33d81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressAddressLine1_49f8900f-0930-46f9-aee6-831123a33d81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_eab9f202-6474-4d00-b719-05103610ea41" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressAddressLine2_eab9f202-6474-4d00-b719-05103610ea41" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_df1c1137-7466-40f3-9275-ab0165314687" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressCityOrTown_df1c1137-7466-40f3-9275-ab0165314687" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a32cd7e2-968b-49de-ad04-ca8c0cb0aef3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressStateOrProvince_a32cd7e2-968b-49de-ad04-ca8c0cb0aef3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2a6f7172-b1c7-40ce-837e-d40354ce2451" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressPostalZipCode_2a6f7172-b1c7-40ce-837e-d40354ce2451" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fcb1b9d0-cd12-49c6-9abe-2aec7dd600f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_WrittenCommunications_fcb1b9d0-cd12-49c6-9abe-2aec7dd600f4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e117869c-e7de-4824-8a4f-0705a582a6b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_SolicitingMaterial_e117869c-e7de-4824-8a4f-0705a582a6b5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_114e4714-8108-4ca1-8d9c-215076dddfa8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_PreCommencementTenderOffer_114e4714-8108-4ca1-8d9c-215076dddfa8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e4aafd7a-993c-41fa-af9b-96351bdef778" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e4aafd7a-993c-41fa-af9b-96351bdef778" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3d33f5f1-d3a8-4bfe-b433-f23e531cdd08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityEmergingGrowthCompany_3d33f5f1-d3a8-4bfe-b433-f23e531cdd08" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d4b7cc5d-65d1-48c0-9c57-83fb5937b266" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_TradingSymbol_d4b7cc5d-65d1-48c0-9c57-83fb5937b266" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b30839dd-5779-4fa8-9e71-cab4735bdaad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_SecurityExchangeName_b30839dd-5779-4fa8-9e71-cab4735bdaad" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_68dfe59e-80a0-4a0f-b932-5969729b7f11" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_DocumentPeriodEndDate_68dfe59e-80a0-4a0f-b932-5969729b7f11" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ace37a97-0243-4dfc-8019-c592948c6826" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityCentralIndexKey_ace37a97-0243-4dfc-8019-c592948c6826" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_689347b9-8f9e-4c2f-848a-4860022828e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_AmendmentFlag_689347b9-8f9e-4c2f-848a-4860022828e6" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_9bc7f42e-01e5-454b-82fe-896fe5050af9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_DocumentInformationTable_9bc7f42e-01e5-454b-82fe-896fe5050af9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis_d7e5795b-b081-4901-b7fe-3e89df83d786" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_9bc7f42e-01e5-454b-82fe-896fe5050af9" xlink:to="loc_dei_DocumentInformationDocumentAxis_d7e5795b-b081-4901-b7fe-3e89df83d786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_d7e5795b-b081-4901-b7fe-3e89df83d786_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_d7e5795b-b081-4901-b7fe-3e89df83d786" xlink:to="loc_dei_DocumentDomain_d7e5795b-b081-4901-b7fe-3e89df83d786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_895448f8-475f-483f-b74b-8b68e04e71e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_d7e5795b-b081-4901-b7fe-3e89df83d786" xlink:to="loc_dei_DocumentDomain_895448f8-475f-483f-b74b-8b68e04e71e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>evh-20230802_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7e6d7619-635a-422d-b18f-38f1cc3dbacc,g:e3cef932-9209-412f-83f3-9c1ffa74c22f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentPeriodEndDate_edff1256-5f8e-4b59-a80e-294b5e490f77_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c2acd9e5-6396-4b64-b142-7e852275fa35_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_387ec0b1-1691-4d82-9c86-89dc36f36765_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d4416b3c-d71a-4c80-b8bb-7952e6cc45ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_cc28d91a-315b-453f-8369-50d8b421a6e9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8ef0296d-cc09-4398-89e1-b7a1e16f1b89_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentDomain_56117fcd-2605-42c0-b39f-251a4757bedc_terseLabel_en-US" xlink:label="lab_dei_DocumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document [Domain]</link:label>
    <link:label id="lab_dei_DocumentDomain_label_en-US" xlink:label="lab_dei_DocumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain" xlink:to="lab_dei_DocumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_af215ca9-3261-4d68-aded-e3eeaab07f08_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b15ff29f-00a0-4836-a748-0a0ccc550d99_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_14c69ad3-1ffa-4706-93e3-4336dc2c7cab_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7e796e59-253c-46ed-b676-e2201a60649d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_078c93ed-f8be-4276-ac03-30a16b2d1230_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_21b11a26-b0a6-47a5-820d-7524df9247af_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d5ccfba8-8538-41df-98ee-efccc347499d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_72c9c71e-c616-40da-b7d4-d4701a00e80b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_037e9d5c-cb61-4c62-a52f-9de96971e1b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_8bd40c08-166f-4824-9cb9-d7cfd7084e2a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_3b270dee-8cee-41ae-a782-20e7fa908c34_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_16773e6d-9d02-4631-bb14-402f98a61021_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_665fd2bf-6608-4ee3-8a9a-4d664b9ea2e1_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_label_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis" xlink:to="lab_dei_DocumentInformationDocumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_98c569c1-0b1d-4217-91ff-4f93a29a6635_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aa770d24-6e0e-44cb-b696-9af1675b208b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_daa4da1a-89c6-4e7a-9e54-635038a19c3c_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_564bf35c-c7f7-4936-a6e9-f451f0bbf60b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_29875d69-9c8b-4d24-b2db-e2f27ca29b7d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6de448f5-3440-49d8-b46a-a2da882a8b99_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_254a5c84-1233-4580-ad14-142c7ecd0a91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_be03e6da-651b-440c-93e6-693cd5187ce9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>evh-20230802_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:7e6d7619-635a-422d-b18f-38f1cc3dbacc,g:e3cef932-9209-412f-83f3-9c1ffa74c22f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="evh-20230802.xsd#CoverPageCoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_73935782-0dae-4692-b4b3-1fd8973b1a4d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_9bc7f42e-01e5-454b-82fe-896fe5050af9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_73935782-0dae-4692-b4b3-1fd8973b1a4d" xlink:to="loc_dei_DocumentInformationTable_9bc7f42e-01e5-454b-82fe-896fe5050af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis_d7e5795b-b081-4901-b7fe-3e89df83d786" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_9bc7f42e-01e5-454b-82fe-896fe5050af9" xlink:to="loc_dei_DocumentInformationDocumentAxis_d7e5795b-b081-4901-b7fe-3e89df83d786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_895448f8-475f-483f-b74b-8b68e04e71e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_d7e5795b-b081-4901-b7fe-3e89df83d786" xlink:to="loc_dei_DocumentDomain_895448f8-475f-483f-b74b-8b68e04e71e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_9bc7f42e-01e5-454b-82fe-896fe5050af9" xlink:to="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7311851a-a26e-436c-bf28-cd4e10979607" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_Security12bTitle_7311851a-a26e-436c-bf28-cd4e10979607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_08d1e2ce-0357-42bd-aea9-db607b6287cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityIncorporationStateCountryCode_08d1e2ce-0357-42bd-aea9-db607b6287cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0ef78876-dff3-43b7-bf7c-3ff45fcced3f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_DocumentType_0ef78876-dff3-43b7-bf7c-3ff45fcced3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3a99cec7-b5d2-4fb0-9361-f6829b06b6d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityRegistrantName_3a99cec7-b5d2-4fb0-9361-f6829b06b6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f50c9475-5561-4061-af59-34704830b2a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_CityAreaCode_f50c9475-5561-4061-af59-34704830b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4f5d47f0-c06e-4a90-89a9-36d1e66541a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_LocalPhoneNumber_4f5d47f0-c06e-4a90-89a9-36d1e66541a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c4d2c76c-1b4b-4914-b1b8-9b4ffea51005" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityFileNumber_c4d2c76c-1b4b-4914-b1b8-9b4ffea51005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fd79f116-d53e-4c56-9738-19271bdf8e98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityTaxIdentificationNumber_fd79f116-d53e-4c56-9738-19271bdf8e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_49f8900f-0930-46f9-aee6-831123a33d81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressAddressLine1_49f8900f-0930-46f9-aee6-831123a33d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_eab9f202-6474-4d00-b719-05103610ea41" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressAddressLine2_eab9f202-6474-4d00-b719-05103610ea41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_df1c1137-7466-40f3-9275-ab0165314687" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressCityOrTown_df1c1137-7466-40f3-9275-ab0165314687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a32cd7e2-968b-49de-ad04-ca8c0cb0aef3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressStateOrProvince_a32cd7e2-968b-49de-ad04-ca8c0cb0aef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2a6f7172-b1c7-40ce-837e-d40354ce2451" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityAddressPostalZipCode_2a6f7172-b1c7-40ce-837e-d40354ce2451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fcb1b9d0-cd12-49c6-9abe-2aec7dd600f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_WrittenCommunications_fcb1b9d0-cd12-49c6-9abe-2aec7dd600f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e117869c-e7de-4824-8a4f-0705a582a6b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_SolicitingMaterial_e117869c-e7de-4824-8a4f-0705a582a6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_114e4714-8108-4ca1-8d9c-215076dddfa8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_PreCommencementTenderOffer_114e4714-8108-4ca1-8d9c-215076dddfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e4aafd7a-993c-41fa-af9b-96351bdef778" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e4aafd7a-993c-41fa-af9b-96351bdef778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3d33f5f1-d3a8-4bfe-b433-f23e531cdd08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityEmergingGrowthCompany_3d33f5f1-d3a8-4bfe-b433-f23e531cdd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d4b7cc5d-65d1-48c0-9c57-83fb5937b266" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_TradingSymbol_d4b7cc5d-65d1-48c0-9c57-83fb5937b266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b30839dd-5779-4fa8-9e71-cab4735bdaad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_SecurityExchangeName_b30839dd-5779-4fa8-9e71-cab4735bdaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_68dfe59e-80a0-4a0f-b932-5969729b7f11" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_DocumentPeriodEndDate_68dfe59e-80a0-4a0f-b932-5969729b7f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ace37a97-0243-4dfc-8019-c592948c6826" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_EntityCentralIndexKey_ace37a97-0243-4dfc-8019-c592948c6826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_689347b9-8f9e-4c2f-848a-4860022828e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_930c8a46-5e94-457e-95c3-12dff2818578" xlink:to="loc_dei_AmendmentFlag_689347b9-8f9e-4c2f-848a-4860022828e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>evhnewlogoa.jpg
<TEXT>
begin 644 evhnewlogoa.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %R R # 2(  A$! Q$!_\0
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M*UCIB/1R=RD'X*^)2NU!@DP[)IVS7:BA$E'6R/'/4Q@[%CA^$]O0[^8WW66
M*BUX,>8<0N,<H&_-+ON?+T3]U*0.@7R_QSC4XW*UCC46C?\ VZF"TVIZJ[KB
M9F@D%P!]Q*Q4XF^*N;%*^HQ7$)PVYQ$LK+@!OZ!W\1F_X0\SY=EA]=<WR"]W
M">NKKS6U%5,[F?(Z=VY/YU;X'P[GY>*,N2W1$]O>?_3A\OQO%Q[SCI7JF/\
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MNLW8_D_%<'QCB8^+GB,7I$QO7V?4?].O'N9XYX;?YV>J^.VNK[QK?K^L>_\
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M;KT(ZA1$^">!^ZGJ2?/["T_UZEW'14<M/*O-4E9W&Q$10MA$1 1$0$1$!$1
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M)"+;4T<=U:UW21TS7"/I\.4J-197>%U<JFBXR<.A@G?%%515<<[&G82-$#W
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M3IIT_=G''KM<9<3V^E<EQ/;Z5QEAK;\2?W?M0_RY5?6.5MO(JY/$G]W[4/\
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M"N'JJH<ER"5N7YQ .9E7*S:DI'^^&,CJ1Y.=U'DLRP-ER\_)ZOP4[)JUUZR
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M&JI8:RGE@GB;-#*TL?'(.9KVD$$$'N""IL66<-MPTM6):N2#HIB>)CPC\3U
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M^&1PSXO3:40ZBWJV4%XOEWG>:.:HC]*:2&-W*  [HUY<"21Y$+M>-' YM,>
MBV8E/5MKIK-%1T3ZEC.42%O0D#R6+G"'QB9#PI88:+(L.K[QAU[E]=M]8Q[H
MRP@ADA8X[M<SV?DC8[H:]&6/B-\-&'9'HK?<]IK=3VG)<?8*OUNCB:PU<9<&
MNCEV^5W!![C96+TBXA\GH?#CSMM/(UM98*MMDIZQ[R]Y@J".;OV+0\@;=ALO
M-<27&WDG%_;:+3?3W$*^DI:^K F:U_IIZT@^PS9HV8WN2#[A[EEYI7P245FX
M0:[2Z]FG;>KY"ZKKJR-IV96'VHB>OM>C(:/CRH=H]6#7!=Q(:7\/UHK;CD.
MW;),PGJB8[M3Q1RM@A ]EL?.=VNW+MR._1=_Q@<4NEG$AA<C;=IY?;1F<,L<
ME-=Y::)O,T=',E<WVG-Y2=A[]E\&D.L>6<!^47W"-1,#9D%D=)Z>..:G8US'
MD[">*5S2',<!V/N\E=?)?$LLE_JZ&W:>Z/4UQKY:F%I];IHWF1I<.:-K&-WY
MCV!)VZHR^)O$%DTGAD53XY*B&YTM>W&*BKJ]W22T[R22TGJ#RD-!\ME[WPO.
M'O#:S28ZAW.UT]XO]97RPPOKH&R"C;$[8>CW[$[[DK)+6_0VAX@N'RMQ<6UN
M,U=PIXZ^FIC&UGJM8&\S1(&CKL3RE1\Z \4V=<"=?>=/-0,3K*ZS13>EAI21
M$^F>X^U)&\C9['@;[(Q'9(;JIP?Z4ZPW.CN.1XM3.K:>7TIGHO\ -WSG;;:4
MLZO;T[%6%\5&UTEDX8+%;Z&!E+1TU[IHH88QLUC1'*  %;*_>)?G^JV8V2SZ
M.X-*9?3D20UC34FK&W8ANW(!U).ZN;XI3ZRLX7<>DK8!!7/O-(Z>%AY@QYAD
MY@#[@=T(]%PO#^J:2BX.,2J*Z6*"BBAJGSRSN#6-8)7\Q<3T VW5D+3QN<.F
MB-]J;)@. 5MYY>9K[O;*.,OJ27.<[=[SSN )/4]/<O4Z$XA>,Y\,_P"P5B?-
M'=:JV5C88XF;OF(E>?1 ?\8'+]*QMX'^)73/ARMM_L.I6(34=ZDJ3(+J;?Z>
M8@>SZ%S'#=H:0>H[[HQ"V7&;K%A&LN866^X?A=?A=4V)[:X55,R#UJ0NYFR>
MQW<.VZD]UY>Z3@;R1SW%SG8>PEQ.Y)] SJHW.-_7FBXA[W:+KBV(55EQ.TF2
MCAN$M*(O7)'>T"0 -O9'0=5)%KJ">!O(@ 2?M/CZ;?\ N&(RQU\'?_U-U)_G
MU)]6]6CU<_\ :H6__J.V_4L5WO!Z8Z/#M20X$?Y]2=QM_JWJT>K<3SXIMO<&
MN+?MCMO4 _[)B'O*6"K@I2QTU3'"61@DR3-&S0.I))[!1@<56JMYXR-9K?HS
MI2^.;':>?_/*R%H;!42L)YYGN'>*/KM[SU'DKB>)WQ2UN*6\Z48VZJI;E<(&
MU%UK8P6@4SM^6)CAW+MCN1V V\U8G@_XJ]+.%[&IWNQ2[WG+K@-J^Z !K6L!
M]F*('LT=S[RA"2GAQX?K#PYZ;46+64FHE'\+6U[V[/JIS\IY]P\@/(*.CAQ_
M]IY>ORQ=_P"Z]9S\+W&)8N)ZOOM+9[)76EUICBD>:P@AX>2!MM\RP:X<HGM\
M3F\N+7!IO-WZ['^*]"/=<KQA8S-0:9L;\IU15@?/LQ9-\*O#;A&GVB>-P#&K
M9/=*ZW1RW&LF@;-)4/D:"\%SAOR^YO8+&GQ>6.?!I?RM)VJ:H] 3Y,6=VDW3
M3+%OR;!_<"'LBIXY\,MW#;Q9XWD.$P06Y\\=->(J&*!K*>GE9*6;-:.G*>3<
M_$E7>\6K4&ZMP[3G'&O8VVW5K[I4M#?:=+&UH9U]W\([I\R\#XL<;G\0>'<K
M7$"RQ=@3_P#B7K,3B]X8G\26AMLH[2V"/*[7%%4VV:<AH?[ #XB[\$.'7YP$
M'W<&G#9A.E^C>+U]':J6OO=TH(JZJNM73L=.\RM#^0';HUN^P'P6-WBD\.&&
M8YA5OU&LE%!9+SZ]'05--1Q-CBK!)S'G<T?A-Y>X[@]5:S3+BIUUX.;=%@N6
M8=4W&UT[I#2172&3TL;=]N6*4;@Q[]0#[^G1>+XJ,NUSUUPVEU"SVR.QO"Z&
M2&GM]%RF"*5\W,1(QCCS2$AO5QZ#8=MT9CNS_P##*^])QO\ G=;]>Y94'Y)6
M+?AH4TM-PE8R)8W1EU36/;SC;=IF=L1\"LI#V*-41W'-_P"T%L?_ ,6R_P!]
MJR_\3[KPGW?\IT?UA6(?'+$]WB"61P:X@2V7J ?X[5E]XGC2[A1NP +C]DZ+
ML-_]849^RWGA?:&X76:(,S2X8_17'(JRXS,%;61"5T4<9V8(^8>QW.^W=6\\
M5[1G$L/MN'Y;8[136BZ5U7+157J438F3-#2\/<!W=OY^Y9!^%\TLX4[2' @B
MX5?0C;\,*VGC ,<_33 0UI)^R\W8$_ZE".[*'A%R:XYCPVZ>WF[5!JKC56J,
MS3$;%Q!+0?S *[I[*Q_! "WA2TT!Z$6IO0_\[E? C<$(PB'X Z^FM?'1>F5D
M\=(^?[*P1-G<&%\AEZ,&_=QV.P4O*C2XZ.$3+\/U,_=LTP;45,WK#*VMI*.(
M&:AG8/\ 31M ZL('7S!W/FOQPSQ=ZZSV*GH\RP!]=>X]Q-54-4*=D@_!/HW@
MD'W]=D929'L5%9XGN;7/-.(3%--7U#Z2RTT=*[^#<2'R5+^4R.;V):.R[&X>
M(-K'K[J/C-KTAQ22U0Q3-FFH7#UDUFQ]L32; -B (WVV(]ZN1XAO"[E6I5FL
M6J&,VUC,LLU(P76WT1+YWM:>8/C=^%Z,@]/,'X(1Z,JM)N&_ ]),%@Q>T6"A
MFIQ3B"KJ:BF8^6M.WM.E)'7<[]/+LHW..[2NW\./$GB>4X0QF/TUQ?'6MIK:
M\QNAG9)M(6 =&-<"  .G=7&TW\6?[7<-H[9F^&5E=D-'3"-]933B)M6YO1KG
M-<-V$C;<]1ONK:6NS9YXAW$O0Y2ZPS6#$K>^%LE0\.,5+31NY@WF=T?*[?R'
M7Z$(W"^7BM71E]T#TZN+6.C95W1LP8_Y30ZF<=C^=>]\.WAWPFT\/^-9?/9J
M.ZW^]L?5RUM;3,DDA',6>C82.C=F_P!J\CXN5/R:.X/%$S9K+T6AK6] ! [W
M*_7 2TMX2--P001;W="/_>O0]F!_BH:9XUIMJ=B5TQ>U0V.LNM%-451H1Z-C
MI(Y &O#1T#NO4CNLZM7JB6JX'+_//(Z::3"N=\CSNY[C3-))/O*P_P#&&B=)
MFNGG*TNVMM7V!_VK5E[JNTG@7O0 ._VD#IMU_P#16HPPS\*;17#]0JG-L@R6
MR4M[JK6ZFIJ2.NC$L4?.'.<_D/3FW:-CY=5?3Q-=&<,9P^U^6P8_1T>06RKI
MF4];21")_*^0,<UW*/:;L>@/8KPW@[QN9CNI0<TM_P ZHNXV_P!6]7N\31I?
MPE9&&@DFLHNPW_UP1GW6^X"\^K+%P*Y%>:^JK*QMFFN#*8,?S/AC:QO(R/W
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<"(B B(@(B("(B B(@(B("(B B(@(B("(B#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140102450662912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  02,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>evh-20230802_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="evh-20230802.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37415</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">389-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX!Z ^RNE[/N)VX\7?Z>,_@=02P,$%     @ !(("5Y^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M0/FNM%%QS:O8<-*5GN?^X7'RI+FTSBT5^PAO9,O1\OA=BU]02P,$%     @
M!(("5R0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
M   (  2" E=ED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V3
M34[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\
MSYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!
M$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY
M<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4Z
MJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C
M2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.
M&G_FB^$_7G\!4$L! A0#%     @ !(("5P=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  $@@)74C43
M_>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  $@@)7F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  2" E>/M4 &=@0  %H1
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  $@@)7GZ ;\+$"  #B#   #0              @ &Y#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  2" E>7BKL<P    !,"   +
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4!08     "0 ) #X"   3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="evh-20230802.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPageCoverPage</Role>
      <ShortName>Cover Page Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="evh-20230802.htm">evh-20230802.htm</File>
    <File>a2q23exhibit991.htm</File>
    <File>evh-20230802.xsd</File>
    <File>evh-20230802_def.xml</File>
    <File>evh-20230802_lab.xml</File>
    <File>evh-20230802_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20230802.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "evh-20230802_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20230802.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20230802_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20230802_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20230802.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 28,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20230802",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230802.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:Security12bTitle",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.evolenthealth.com/role/CoverPageCoverPage",
     "shortName": "Cover Page Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20230802.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:Security12bTitle",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.",
        "label": "Document [Domain]",
        "terseLabel": "Document [Domain]"
       }
      }
     },
     "localname": "DocumentDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_DocumentInformationDocumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Document Information, Document [Axis]",
        "terseLabel": "Document Information, Document [Axis]"
       }
      }
     },
     "localname": "DocumentInformationDocumentAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628908-23-000119-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-23-000119-xbrl.zip
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M+PF 6IB^JJ 0.^HN(I&ZK=?'IM'9K:F[U2:N^S,'@LFX%?6M[QLMD)86?"X
MV@%B#1%VH(DD\K;3Z%;=Z6T@@D:KVOK!GN("D"'G0%%A.DQ*5&$I@G#7$(2!
MY',A^0=/K2!*$HNE:2QZ68KL#+@9\DL B94,@?4-H\#G<8+P7,JQ"0V<:B,'
ML^)YJ(4"@V96F']$P@N?O^E4.R]_J!K('@RRMSYN"A#3VU_??WES*X'47@FD
MT)I_80HLIU9U?C!D>$!@?8E24!5^%P^@N0!H/@4L!7UAA)O?[E1;4D,HF&@V
MEMS3Z58;,[<*)>-)GKHK+)U:1T]@=MLU]_3 ;-#"[T#7C!+8<P!?O=J9!5%
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MB)Q->:(!,*A@(QZ!=HUR+IAL:.P;T#T)NCL4'@"WLL>_WG1*\"(0NHUNM6U
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M(A4YH717-$QE78K,4::0.+Y4)':I>98SK&2R%B61H06%&6/WF3=4DQBQ25Z
M+$9RC?#3SN=N#9B@JB?0SL.D+U/)5 KM4(QE+C3Y[*B,<LPF(\J(:K1? _4
M.&$:0XJBPWL^[Z7R#1J5OHHNBG0"0P(0D+,]<( -9HZH+&Q\CHG8>F"!M/T
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M;,&G-D[;K.O),.3G?5 SY3)?T0-**]8D=\QM5[N4._9F%:6#/3IB,7R[X"]
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M?IDR"V:^+9(%ZZS(XPHQWN%E 2MM\[0F8T4^^C!ZY-2&>!D$IM^/::!Y8%!
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M+/#3%P^__ S_Y&^4YH>>1M&?*%#]\G,/WU,[./^:VN]Z"P RCA*!SLI7% X
M4^GUH_#3H0)&^2VUL[7I*ZP'FYBEJU\IS<\#BXK'>\(DYRE,<LG',KL!Y7]Q
MCL+_YPOA]NO-+F=.T^^[#=?SNUZ=\V:CYKBMMN_W_?\XM1?Y2\/"DAZS :_T
M8LZ^5E@?EO6*!8]LDLPN?B3"?#X-=%[/;])*2*T#\T&W<2&;D+9QK3FLUU3O
MHM '@Y_[%OQ&!$X1KE]9P$*/6_=#SM/DY'-?CJTW(K32893!&'YB6UG(,E_
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MSM8-48T:<QQ/2;-A=QON17I+]#Z ?A<6PF')*YG'AB+ G,IVL&W1D<#=&JB
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M)D)B(GGG: 1!+J> W5ET<_WC2/:H[_9XKI2B_)YJ*3D70#4_*PM08#]2FAL
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M,!9[5UL21%<Z<3""/WTY"-O_#U!+ P04    "  $@@)736H!UH("  "C"
M$    &5V:"TR,#(S,#@P,BYX<V3555U/VS 4?>^O\/(\-U\,FH@6:2"D2=V&
M&&B\3:YSDU@D=F8[;?GWV&ZR-E 8G?:PY24WU^?<CV-?Y_1L75=H"5(QP:=>
M. X\!)R*C/%BZMW>7.*)=S8;C4[?87SW\7J.+@1M:^ :G4L@&C*T8KI$N@3T
M7<A[MB3HJB(Z%[+&>.9HYZ)YD*PH-8J"*.YA_:I,3^ X.SD.$WP<?R#X*(HR
MO @G.8XG>4AIG"T(I>^+%&(*>1)'.(F"!!^%48XG<1[CA(9Y3DZ.:&0\-NA:
MI8J64!-D6N,J7:NI5VK=I+Z_6JW&JW@L9.%'01#Z=Y_GWQS4Z[ 5X_<#]'HA
MJQX?^W9Y013T<%B6 S0L166T*8%4NAQ34?NVY6 21!XB6DNV:#5<&FTN("=M
MI:=>RW^VI&(Y@\P(7X&5=@#86=9$%J"_D!I40RB\-?-LA) 5A=6-D!KQO?Q.
ME3!)$G]MV_301L2YH$2[L_&B*@Z/K8G#",?A>*TRSW]3VF$@QI4FG,(AN<T7
M[GE_HX;M%A]60\\[O 873 $=%V+I9\#<SNU/KUZ"6P-;8YB3<"ZTXUM/YVL:
MQG.Q<1B7+3SMJ[^&O)^:9Z.PYXBX5THDE>;TO0[V&RD:D)J!VATC%Z"4D$\]
M,TRX/[0_*K(8FT)ZQ+/XPQVPR[ZA0#7?-M)S]4-CN,KH7\%&FG^X[T;"H7T;
MBC*C[[;Y?V\_@_S0]@V%<?8'S5OVC5E'+)MZY\+\ Z]( ;\,#UG [?6GW]RS
MKH@]]#Y9GVY;YRQP3XCP]F^*D6,B2]TQ3_VGW"=16P795SYS]M.#T)$[R"M$
M2BK:5H?SAM+OI77.7NON&O*']]#F>^>N<H[-!3@;/0)02P,$%     @ !(("
M5]%<:@<?"   L#H  !0   !E=F@M,C R,S X,#)?9&5F+GAM;-U;VW+;.!)]
MSU=HM:\+"U<"<,69RCK)EFLR$U?BJ9G:%Q4N#8D5BG11].WOMRE;B6TQ\8S!
MS%;I11<(0I_NTVQT-\&7/UVOJLDEM.NRJ8^F[(!.)U"')I;UXFCZV]D[8J8_
MO7KQXN4_"/GCWQ_?3]XTX6(%=3<Y;L%U$"=79;><=$N8_-ZTG\M+-SFM7)>:
M=D7(J\W?CIOSF[9<++L)IUQLIVU_;0\U%%$7S))"*$<DYY%X9A(1)K$01/0N
MA'\M#D$$2%9P8CFU1#*>B!%)$!M82D[+P'&D7[0JZ\^'_8MW:YB@>O5Z\_5H
MNNRZ\\/9[.KJZN#:M]5!TRYFG%(QV\Z>WDV_WIE_)3:SF;5VMOGUR]1U.301
MEV6S/WYY_RDL8>5(6:\[5X>O E!\[+[\\3X:-;O]$:>NR\/UYO_OF^"Z#4%/
MJC#YYHS^&]E.(_T089P(=G"]CM-7+R:36\NY-K1-!1\A3>X^_O;Q9!=I67>S
M6*YF=W-FKJH0\6:%[N8<CJ;K<G5>P79LV4+Z)OJMRCTHU</Y9[_:+!O3$H&T
MX<(#P5&H>Q<?$>/0ZOF8OZQ%(B1W474C(MY=>U2\S<J58QIX9^D1T&X6(BM8
M>6C'A/I@W7LXMR ?(^R7A$L<K#%TNJI;'H1F-=M@/&XP')^Z!7SY\#10N%R2
M/KI20_D&T, B]U A_65=]A'E/7Z]6ZD7/@8^N.Z@CA"GDS(>3<OHK(R%I.!#
MDE()+SQ8X7FB6BOE^'Q@O1[I%FO5A ?+5WTL;+Z05SD/U69T'J&<;[>GD[K?
M@MR=BG#2P6H]MX(&XV1!%%A)I-) K I]&(PI<<.,TF;7 =9;AUI#.%@TES.4
M,^N-W7_86/W6!9Z0?FO_YVGU"<)%6W8WC/NSLJM@K@5#M,P1QPL@4A2!>-2
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MF\;*A_:T;2[+.L#<"1ZB!DYL8?IT(@)QD4H2G DT>.H@B?&X?B1]WPC/,>X
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M[R[C2NY_OG^UN9*N_IO ]Z_^!U!+ P04    "  $@@)7X3V4L:L'   $/0
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M/33[YL5_ 5!+ 0(4 Q0    (  2" E<:1=F,PTT  #6-!  3
M  "  0    !A,G$R,V5X:&EB:70Y.3$N:'1M4$L! A0#%     @ !(("5T+\
M)WYR$@  YX,  !               ( !]$T  &5V:"TR,#(S,#@P,BYH=&U0
M2P$"% ,4    "  $@@)736H!UH("  "C"   $               @ &48
M979H+3(P,C,P.# R+GAS9%!+ 0(4 Q0    (  2" E?17&H''P@  + Z   4
M              "  41C  !E=F@M,C R,S X,#)?9&5F+GAM;%!+ 0(4 Q0
M   (  2" E>X/=RU+@P  /9Q   4              "  95K  !E=F@M,C R
M,S X,#)?;&%B+GAM;%!+ 0(4 Q0    (  2" E?A/92QJP<   0]   4
M          "  ?5W  !E=F@M,C R,S X,#)?<')E+GAM;%!+!08     !@ &
+ (,!  #2?P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
